TriangleEAGD T-cell (NCT03533816)
EAGD T-cell trial for Acute Myeloid Leukemia (NCT03533816). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
For many leukemias, a bone marrow transplant is the only cure: the donor's immune cells finish the leukemia. The same cells can also attack the patient, called graft-versus-host disease, and with a half-matched donor the risk climbs.
The idea: keep the cells that kill leukemia, and leave behind those that start the war.
Most T cells are the alpha-beta kind, which cause graft-versus-host disease. A small minority, gamma-delta T cells, recognize cancer cells directly, without the matching that triggers attacks on healthy tissue. From the donor's blood, those cells are pulled out, multiplied, and infused after transplant.
At Kansas and Ohio State, with Joseph McGuirk, the trial asks whether that is safe, and whether relapse and graft-versus-host disease drop. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.